Red Cell-Derived Microparticles for Hemostasis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for excessive bleeding, such as blood transfusions, face challenges including scarcity, high costs, and adverse reactions due to immunogenicity and thrombogenic risks, necessitating a safer and more immediate treatment option.

Innovation Solution

A composition of red cell-derived microparticles (RMPs) with reduced acetylcholine esterase activity, optimized phosphatidylserine display, and minimal lipid raft content, which can be administered without cross-matching and have a prolonged shelf-life, effectively shortening clot formation time and reducing toxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If blood transfusions are administered to treat excessive bleeding, then bleeding is controlled, but the treatment becomes expensive and scarce due to rising demand and limited supply

Engineering Contradiction:

Improvebleeding control effectivenessVSAvoidblood supply availability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent extracts the essential hemostatic function from whole blood by isolating platelet microparticles (PMPs) that contain the necessary coagulation factors and phospholipids. This extraction allows the therapeutic effect to be delivered without requiring large volumes of whole blood, thereby resolving the contradiction between effective bleeding control and limited blood supply availability

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent segments the complex blood system into functional components by identifying and isolating platelet microparticles as the active hemostatic element. This segmentation enables targeted therapy using only the necessary components rather than transfusing entire blood units, improving supply efficiency while maintaining therapeutic effectiveness

Inventive Principle:

Principle #1Segmentation

2Reliability

If platelet transfusion is used to arrest bleeding due to low platelet counts, then hemostasis is achieved, but the treatment carries high cost and risk of thrombogenesis due to tissue factor carriage

Engineering Contradiction:

Improvehemostasis achievementVSAvoidthrombogenic risk

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by modifying the microparticle composition to have specific functional characteristics - enriching for phosphatidylserine exposure and coagulation factors while controlling tissue factor content. This creates microparticles with localized pro-coagulant properties that promote hemostasis at the bleeding site without excessive systemic thrombogenic risk

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes key parameters of the microparticles including phosphatidylserine display level, tissue factor content, and size distribution to optimize the balance between hemostatic efficacy and thrombogenic risk. These parameter adjustments allow the microparticles to be sufficiently pro-coagulant to stop bleeding while minimizing harmful thrombus formation

Inventive Principle:

Principle #35Parameter changes

3Reliability

If platelet transfusion is administered to treat bleeding, then clot formation is promoted, but adverse reactions occur frequently due to high immunogenicity from HLA, ABO, Rh, and platelet-specific antigens

Engineering Contradiction:

Improveclot formation promotionVSAvoidadverse reaction frequency

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent creates artificial platelet microparticles that copy the essential hemostatic functions of natural platelets - including phosphatidylserine exposure, coagulation factor content, and pro-coagulant activity - while using different material composition that lacks the immunogenic antigens. This copying approach maintains therapeutic effectiveness while eliminating the harmful immunogenic properties

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent employs synthetic or engineered microparticles that can be produced without requiring cross-matching and have reduced immunogenicity compared to donor platelets. These microparticles function as disposable hemostatic agents that provide the necessary clot formation promotion without the frequent adverse reactions associated with immunogenic platelet transfusions

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The RMP composition significantly reduces bleeding while minimizing adverse effects, providing a safe, immediate, and cost-effective solution for excessive bleeding by promoting hemostasis and reducing thrombogenic potential.

Implementation Method 1

RMPs have an indefinite shelf-life with room temperature storage and do not require storage in blood banks, making them particularly advantageous for emergency situations. Additionally, RMP produced from type O Rh negative red cells (universal RMP) can be administered immediately without cross-matching.

Methodology Applied

Scientific EffectCoagulation: Coagulation